Larry Ramer

Larry Ramer

InvestorPlace Contributor

Larry Ramer has more than 15 years of experience in business journalism. He has worked for Globes, Israel’s most widely read business newspaper, as well as The Jerusalem Post and theflyonthewall.

Mr. Ramer’s expansive knowledge of politics enables him to provide valuable insights into how politics can affect stocks. He also focuses on contrary investing and specializes in the renewable energy and consumer discretionary sectors.

Among his highly successful, contrarian picks have been Super Micro Computer, Intel, and MGM Resorts.

You can reach him on StockTwits at @larryramer and learn more about his stock-picking record at his TipRanks profile.

Recent Articles

Alibaba Stock Will Struggle to Overcome These Short-Term Headwinds

By Larry Ramer, InvestorPlace Contributor

Alibaba stock is facing threats from JD.com and the U.S.-China Cold War. This has led to weak sentiment towards Alibaba that should linger.

The Challenges Facing Shopify Stock Are Intensifying

By Larry Ramer, InvestorPlace Contributor

Shopify's Q1 results shows that the challenges facing Shopify stock are intensifying. Its small business customer base is likely to shrink.

Powerful Biases Obscure the Strong Long-Term Bull Case for Boeing Stock

By Larry Ramer, InvestorPlace Contributor

Biases are preventing investors from seeing that Boeing stock, down tremendously from its highs, is a very good pick for long-term investors.

Buy PayPal Stock for Contactless Payment and E-Commerce Trends

By Larry Ramer, InvestorPlace Contributor

Market share gains, a virtuous cycle and a newly acquired app are among the positive catalysts that should lift PYPL stock.

Starbucks Stock Is Overvalued With Multiple Headwinds Looming

By Larry Ramer, InvestorPlace Contributor

Starbucks stock has multiple, negative catalysts, some of which will linger a long time after the pandemic ends.

Buy Good News Gilead Stock Before Other Investors Catch On

By Larry Ramer, InvestorPlace Contributor

Positive signs continue to mount for remdesivir, yet the market continues to have mixed feelings about GILD stock.

Sell Salesforce Stock Now in Favor of Amazon or Microsoft

By Larry Ramer, InvestorPlace Contributor

Salesforce was struggling to grow its business even before the pandemic. Sell CRM stock and check out one of these bigger names instead.

Favorable Oil, Macro Trends Will Boost Exxon

By Larry Ramer, InvestorPlace Contributor

With lockdowns easing and a strong economic rebound likely in 2021, Exxon Mobil stock should benefit from a short- and long-term boost.

Why iBio Stock Could Soar 500% Above Its Current Levels

By Larry Ramer, InvestorPlace Contributor

IBIO stock is backed by promising technology in its efforts to make a coronavirus vaccine and a well-connected partner.

Gilead Stock Still Looks Poised to Prove the Bears Wrong

By Larry Ramer, InvestorPlace Contributor

With remdesivir poised to become a blockbuster drug for Gilead, GILD stock still looks poised to prove the bears wrong

Load More